Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

Journal of Clinical Pathology

Volumn 61, Issue 9, 2008, Pages 1038-1040

  Furusato, B ^a,c   Rosner, I L ^b   Osborn, D ^b   Ali, A ^c   Srivastava, S ^c   Davis, C J ^a   Sesterhenn, I A ^a   McLeod, David G ^b,c,d  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d Center for Prostate Disease Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CLINICAL ARTICLE; FOLLOW UP; GLEASON SCORE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; BLOOD; CANCER STAGING; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; PROSTATE; PROSTATIC NEOPLASMS; TUMOR VOLUME;

ADULT; AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 51349146598     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2008.057794     Document Type: Article

References (17)

1. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
2. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-11.
3. Goto Y, Ohori M, Arakawa A, et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-63.
4. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994;44:862-7.
5. Chan TY, Chan DY, Stutzman KL, et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001;166:2181-4.
6. Noguchi M, Stamey TA, McNeal JE, et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-9.
7. Elgamal AA, Van Poppel HP, Van de Voorde WM, et al. Impalpable invisible stage Tie prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 1997;157:244-50.
8. Augustin H, Hammerer PG, Graefen M, et al. Insignificant prostate cancer in radical prostatectomy specimens: time trends and preoperative prediction. Eur Urol 2003;43:455-60.
9. Epstein J, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
10. Dugan JA, Bostwick DG, Myers RP, et al. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
11. Stamey TA. More information on prostate specific antigen and prostate cancer. J Urol 2003;170:457-8.
12. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792- 7.
13. Desai A, Wu H, Sun L, et al. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. Prostate Cancer Prostatic Dis 2002;5:212-8.
14. Ochiai A, Trpkov K, Yilmaz A, et al. Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 2007;177:907-10.
15. Cheng L, Jones TD, Pan CX, et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005;18:1022-6.
16. Sengupta S, Blute ML, Bagniewski SM, et al. After radical retropubic prostatectomy "insignificant" prostate cancer has a risk of progression similar to low-risk "significant" cancer. BJU Int 2008;101:170-4.
17. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.